The Technical Analyst
Arcellx, Inc. [ACLX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Arcellx, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.71% $54.47
America/New_York / 18 apr 2024 @ 12:34
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 875.57 mill |
| EPS: | -1.470 |
| P/E: | -37.05 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 52.80 mill |
| Avg Daily Volume: | 0.455 mill |
| RATING 2024-04-18 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -37.05 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -6.30x |
| Company: PE -37.05 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$64.32 (18.10%) $9.86 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 51.73 - 57.67 ( +/- 5.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Elghandour Rami | Sell | 14 919 | Common Stock |
| 2024-04-01 | Elghandour Rami | Sell | 5 456 | Common Stock |
| 2024-04-01 | Elghandour Rami | Sell | 2 711 | Common Stock |
| 2024-03-22 | Heery Christopher | Sell | 10 000 | Stock Option (right to buy) |
| 2024-03-26 | Heery Christopher | Sell | 5 450 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -47.23 |
| Last 100 transactions |
| Buy: 1 139 823 | Sell: 3 751 128 |
Forecast:
14:13 - $54.99
Live Trading Signals (every 1 min)
Forecast
1: 12:43 - $54.51
Forecast 2: 13:33 - $54.89
Forecast 3: 14:13 - $54.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $54.47 (1.71% ) |
| Volume | 0.142 mill |
| Avg. Vol. | 0.455 mill |
| % of Avg. Vol | 31.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACLX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $61.53 | N/A | Active |
|---|
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Latest Press Releases
2024-04-04 16:00:00 - Press Release
Arcellx To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Redwood city, calif.--(business wire)--arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on wednesday, april 10, at 12:45 p.m. et. a live webcast of this discussion will be accessible from arcellx's website at www.arcellx.com in the inv.
2024-03-20 16:00:00 - Press Release
Arcellx To Participate At The H.c. Wainwright 2nd Annual Cell Therapy Virtual Conference
Redwood city, calif.--(business wire)--arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the h.c. wainwright 2nd annual cell therapy virtual conference on tuesday, march 26, at 1:00 p.m. et. a live webcast of this discussion will be accessible from arcellx's website at www.arcellx.com in t.
2024-02-29 16:00:00 - Press Release
Arcellx To Participate At The Td Cowen 44th Annual Health Care Conference
Redwood city, calif. , feb. 29, 2024 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the td cowen 44th annual health care conference on wednesday, march 6, at 2:50 p.m.
2024-02-28 16:00:00 - Press Release
Arcellx Provides Fourth Quarter And Year-end 2023 Financial Results And Business Highlights
-- expanded strategic partnership with kite -- -- presented continued robust long-term responses from phase 1 expansion trial of anito-cel (formerly cart-ddbcma) in patients with relapsed or refractory multiple myeloma -- -- ended the quarter with $729.2m, extending cash runway into 2027 -- redwood city, calif. , feb. 28, 2024 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended december 31, 2023.
2023-12-08 16:00:00 - Press Release
Arcellx Announces Continued Robust Long-term Responses From Its Cart-ddbcma (anito-cel) Phase 1 Expansion Trial In Patients With Relapsed Or Refractory Multiple Myeloma At Ash
-- median duration of response, progression free survival, and overall survival rate not reached with median follow-up after cart-ddbcma (anito-cel) infusion of 26.5 months – -- the estimated median progression free survival by kaplan-meier is 28 months -- -- oral presentation at ash will be on monday, december 11, 2023 at 5 p.m. pt -- -- company to host a live webcast event with an expert panel of clinicians on monday, december 11 at 8 p.m.
Latest News
2024-04-04 09:41:06 - Zacks Investment Research
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-20 16:00:00 - Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in t.
2024-02-28 20:31:12 - Zacks Investment Research
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.
2024-02-15 11:57:01 - InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
2024-01-16 13:51:12 - InvestorPlace
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
2023-12-15 17:04:19 - InvestorPlace
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
2023-11-30 21:37:11 - InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
2023-11-16 11:16:07 - Zacks Investment Research
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
2023-11-15 11:03:13 - Proactive Investors
Arcellx stock climbs on Gilead investment
Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration. Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.
2023-11-15 06:23:00 - Market Watch
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expanded collaboration. Under terms of the investment, Gilead will buy 3.24 million Arcellx shares for $200 million, which will give Gilead a 13% stake in Arcellx, and extend Arcellx's cash runway into 2027.